Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study)
Technology in Cancer Research & Treatment · 2024
DOI: 10.1177/15330338241264169 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Yingying Xu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Ascites, Infusions, Parenteral, Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Subject construction support project of the Second Affiliated Hospital of Soochow University, National Natural Science Foundation of China, Open Project of Provincial Key Laboratory of Soochow University.
Abstract (Originalsprache)
Objective
The prognosis of malignant tumors with peritoneal metastases and cancerous ascites has generally been poor, with limited treatment options. The PRaG regimen, which comprised of hypofractionated radiotherapy, programmed cell death-1 (PD-1) inhibitor, and granulocyte-macrophage colony-stimulating factor (GM-CSF), showed a survival advantage in patients with advanced solid tumors who failed at least the first line of standard systemic treatment. Intraperitoneal infusion of PD-1 inhibitors may be a novel therapeutic strategy for managing malignant ascites. Integrating the PRaG regimen with intraperitoneal perfusion of a PD-1 inhibitor might control malignant ascites and provide further survival benefits in these patients. This proposed study aims to investigate the safety and efficacy of intraperitoneal infusion of serplulimab in combination with the PRaG regimen in patients with simultaneous advanced solid tumors and cancerous ascites who fail at least the first-line treatment.
Methods
This proposed study is a prospective, single-arm, open-label, multicenter clinical trial. All eligible patients will receive 2 cycles of intensive treatment, a combination of PRaG regimen with an intraperitoneal infusion of PD-1 inhibitor. The patients who are beneficially treated with intensive treatment will receive consolidation treatment every 2 weeks until ascites disappear, disease progression occurs, intolerable toxicity occurs, or for up to 1 year. Phase I of this study will be conducted using a modified 3 + 3 design. The dose of intraperitoneal infusion of PD-1 inhibitor for phase II will be determined according to dose-limiting toxicity evaluation in the phase I study.
Conclusion
This prospective, open-label, multicenter study will potentially lead to intraperitoneal perfusion of a PD-1 inhibitor being a new strategy for malignant ascites patients and provide a meaningful efficacy and safety of the combination of PRaG regimen with an intraperitoneal infusion of PD-1 inhibitor for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Institution of Radiotherapy and Oncology, Soochow University, Suzhou, China.
- Laboratory for Combined Radiotherapy and Immunotherapy of Cancer, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Nuclear Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Peifeng Zhao
Förderung
- the Subject construction support project of the Second Affiliated Hospital of Soochow University
- National Natural Science Foundation of China
- Open Project of Provincial Key Laboratory of Soochow University
- Suzhou Radiotherapy Clinical Medical Center
- Wu Jieping Medical Foundation
- Key Medical Discipline Construction Unit of Jiangsu Province for the 14th Five-year plan
- Foundation of Chinese Society of Clinical Oncology
- the Project of State Key Laboratory of Radiation Medicine and Protection
Zitieren
APA
Xu, Y., Kong, Y., Ma, Y., Xu, M., Yang, J., Zhang, J., Chen, R., Chen, G., Hong, Z., Zhao, X., Zhang, C., Xing, P., Zhang, L., & Zhao, P. (2024). Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study). Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241264169
Vancouver
Xu Y, Kong Y, Ma Y, Xu M, Yang J, Zhang J, et al. Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study). Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241264169
BibTeX
@article{Xu2024,
author = {Xu, Yingying and Kong, Yuehong and Ma, Yifu and Xu, Meiling and Yang, Jiabao and Zhang, Junjun and Chen, Rongzheng and Chen, Guangqiang and Hong, Zhihui and Zhao, Xiangrong and Zhang, Chenyang and Xing, Pengfei and Zhang, Liyuan and Zhao, Peifeng},
title = {Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study)},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
doi = {10.1177/15330338241264169}
}
EUVIMED